tert-butyl 2-(bis(2-hydroxyethyl)amino)acetate | 660440-94-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl 2-(bis(2-hydroxyethyl)amino)acetate
• 英文别名: bis-N,N-(2-hydroxyethyl)glycine tert-butyl ester；tert-butyl 2-[bis(2-hydroxyethyl)amino]acetate
• CAS: 660440-94-8
• 化学式: C₁₀H₂₁NO₄
• mdl: MFCD16152336
• 分子量: 219.281
• InChiKey: KSRCFJNCZBTFNF-UHFFFAOYSA-N

物化性质

• 沸点：
  334.5±27.0 °C(Predicted)
• 密度：
  1.099±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  70
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-(bis(2-hydroxyethyl)amino)acetate 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 scandium tris(trifluoromethanesulfonate) 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 (Bis-{2-[2-({2-[2-(2-amino-ethoxy)-ethoxy]-ethylcarbamoyl}-methoxy)-acetoxy]-ethyl}-amino)-acetic acid tert-butyl ester; compound with trifluoro-acetic acid
  参考文献：
  名称：

  A New Aliphatic Amino Prodrug System for the Delivery of Small Molecules and Proteins Utilizing Novel PEG Derivatives

  摘要：

  A new amino PEG prodrug system, based entirely on aliphatic structures, has been designed using ester derivatives easily synthesized from N-modified bis-N-2-hydroxyethylglycinamides. Hydrolysis of the various promoiety bonds, in vivo, regenerated amine in a predictable manner. Thus, a novel new methodology for controlled release of amino-containing drugs, peptides, and proteins has been accomplished. This work demonstrates the usefulness of a PEG prodrug strategy that results in solubilization of insoluble amino-containing drugs and provides prodrugs with relatively long circulating half-lives. It can be appreciated that this novel system should also be applicable for nonpolymer-containing prodrugs as well.

  DOI：

  10.1021/jm030369+
• 作为产物：
  描述：

  溴乙酸叔丁酯 、 二乙醇胺 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以89 %的产率得到tert-butyl 2-(bis(2-hydroxyethyl)amino)acetate
  参考文献：
  名称：

  [EN] POLYMER-DRUG CONJUGATES
  [FR] CONJUGUÉS POLYMÈRE-MÉDICAMENT

  摘要：

  A polymeric scaffold useful for conjugating with a targeting moiety can form a targeting moiety-polymer-drug conjugate. A targeting moiety-polymer-drug conjugate is prepared from the polymeric scaffold. Compositions comprise the conjugates. Methods of their preparation and methods of treating various disorders with the conjugates or their compositions.

  公开号：

  WO2023179521A1

文献信息

• 一种奎宁酮衍生物的制备方法
  申请人：广东东阳光药业有限公司

  公开号：CN110922401B

  公开（公告）日：2022-07-26

  本发明提供了一种奎宁酮衍生物的制备方法，属于医药化工领域；本发明所述方法通过将二乙醇胺衍生物为起始物料，经过氯代或者甲磺酸、与丙二酸二乙酯环合、Dieckmann Condensation、得到3‑奎宁酮衍生物。该方法生产得到的产物纯度高，收率高，成本低，操作简单，工艺稳定的特点。
• Oligomer-Calcimimetic Conjugates and Related Compounds
  申请人：Riggs-Sauthier Jennifer

  公开号：US20120238621A1

  公开（公告）日：2012-09-20

  The invention relates to (among other things) oligomer-calcimimetic conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.

  本发明涉及寡聚体钙敏受体配体结合物和相关化合物。本发明的结合物在通过多种给药途径之一给予时，表现出优于以前给予化合物的优点。
• Oligomer-Calcimimetic Conjugates and Related Compunds
  申请人：Nektar Therapeutics

  公开号：US20140323565A1

  公开（公告）日：2014-10-30

  The invention relates to (among other things) oligomer-calcimimetic conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.

  该发明涉及（除其他外）寡聚物-钙敏感受体结合物和相关化合物。该发明的结合物在通过多种给药途径的任何一种给予时，表现出优于先前给予化合物的优点。
• JP5792175
  申请人：——

  公开号：——

  公开（公告）日：——
• The synthesis and biological activity of lipophilic derivatives of bicine conjugated with<i>N</i>³-(4-methoxyfumaroyl)-<scp>L</scp>-2,3-diaminopropanoic acid (FMDP)—an inhibitor of glucosamine-6-phosphate synthase
  作者：Dominik Koszel、Izabela Łącka、Katarzyna Kozłowska-Tylingo、Ryszard Andruszkiewicz

  DOI：10.3109/14756366.2011.582039

  日期：2012.4.1

  A series of bis-N,N-(2-hydroxyethyl)glycine (bicine) derivatives, conjugated with an inhibitor of glucosamine-6-phosphate synthase, have been synthesized and their lipophilic and antifungal properties have been tested. The obtained compounds demonstrated higher lipophilicity than free inhibitor (FMDP) and, in consequence, an increased potential to cross the cytoplasmic membrane. All the tested compounds show better antifungal activity than parent compound.